Xing Ziqiang, Chief China Economist at Morgan Stanley and a board member of the China Chief Economist Forum, shared his outlook for China's macro economy through 2027 at the bank's closed-door meeting this week, based on current market conditions.
Xing said that although 2027 will still be a period of bottoming out, he does not agree with the extremely pessimistic narratives currently circulating. He noted that while shortcomings in domestic demand cannot be ignored, three structural changes are quietly taking place on the supply side in China.
Two Super Investment Cycles Both Need China: AI Infrastructure and Energy Transition
Looking at 2027 from today's vantage point, China remains in a continuation of K-shaped divergence. But despite the ongoing bottoming process in 2027, we do not quite agree with some of the very pessimistic views out there. While the shortfall in domestic demand cannot be overlooked, three structural shifts are occurring on the supply side in China.
First, the world currently has two super-cycles: one in AI infrastructure and one in energy transition. Neither of these massive investment super-cycles can function without China, which means China's exports may remain strong next year, with year-on-year growth likely still in double digits.
Second, as AI enters its next phase, it will certainly not be confined to writing code in Silicon Valley cloud factories. It will enter China's countless factories to manufacture everything. China holds a significant advantage here because, first, China has no power shortage. Data centers in the United States already consume 6.5% of the national electricity supply and will face constraints ranging from politics to the power grid. In China, however, data centers consume only 2% of national electricity. Beyond that, there is the massive grid upgrade investment, energy storage investment, and green power foundation under the 15th Five-Year Plan, combined with smart factories, networked industrial equipment, and the engineer dividend. As we see it, only China can truly convert embodied intelligence and physical intelligence into real-world applications. Therefore, we expect that industrial 5.0 investment in the coming years will not be about spreading out to build new plants, but more about intelligent upgrading of existing factories, such as using AI agents and robots to improve efficiency, reduce costs, and raise yield rates at existing plants, rather than blindly expanding terminal production capacity. These three are significant, subtle changes on the supply side.
Morgan Stanley Chief China Strategist Laura Wang: Overweight Risk Assets, Bullish on US Equities
The biggest headline from our global strategy outlook is that we remain highly focused on and enthusiastic about risk assets. In our 2027 multi-asset allocation framework, the largest change is that we have increased our overweight in risk assets and equities to the maximum level. We have a 15% overweight in equities, giving them a 70% weight in the overall portfolio. One implicit recommendation here is that we are certainly very bullish on the US stock market, the world's largest single equity market. We are officially overweight three markets: the US, Japan, and Europe. For the S&P 500, we forecast a year-end 2027 target of 8,700 points, implying roughly 15% upside. For the MSCI Europe Index, our target is 3,030 points, also implying about 15% upside. For the Nikkei Index, our target is 4,800 points, implying the largest upside of over 20%.
Gold Target at $5,000 per Ounce, Oil Seen at $75 per Barrel by End of 2027
We also have some important changes in commodities. First, gold remains a category we continue to favor among commodities, with a target price of $5,000 per ounce, unchanged. On copper, however, we believe that although short-term supply is relatively tight, the overall trend will gradually loosen through 2027. As a result, we have shifted our copper outlook from relatively optimistic to more cautious. At the same time, we are more bearish on oil prices, seeing $75 by the end of 2027. On currencies, we are slightly bearish on the yen, expecting a rate of 162 yen per dollar by the end of next year.
Maintaining Market-Weight on China: Potential Earnings Downgrade Risk Ahead
So how should we allocate to Chinese equity assets? We believe that after a tumultuous 2026, especially in recent weeks with the series of disputes between China and the US over artificial intelligence and even greater uncertainty on the supply side for future chips, does this mean we are more bearish on the Chinese market? First, let me state our view: we have not changed our market-weight recommendation on China within emerging markets. In terms of earnings growth, we forecast 8% earnings growth for the MSCI China Index in 2027, and a recovery to 11% in 2028. At that earnings growth rate, where is the MSCI China Index currently trading? At 9.6 times 12-month forward price-to-earnings. That level is still some distance from the historical trough valuation of 8 times. Additionally, at 9.6 times, the MSCI China Index still carries a 14% premium relative to emerging markets. So from both an earnings growth and overall valuation perspective, we do not see the necessity to upgrade China to overweight; there is no urgency at this point. However, our 2027 earnings growth of 8% is actually a modest upgrade from our 6% estimate for 2026. One reason is that we believe the next three to four quarters of earnings reports, as well as first-half 2027 reports, may show a very clear process of market expectations being revised downward, creating a low-base effect in 2026. The second reason is modest renminbi appreciation. The third reason is that compared to 2026's overly concentrated AI trade, as 2027 unfolds, with oil prices stabilizing and declining and global yields stabilizing and declining, allocation opportunities in different sectors can actually open up.
Biopharma Upgraded to Overweight, Internet Sector Downgraded to Underweight
On sector allocation, we continue to recommend exposure to high-tech, high-precision sectors that align with China's medium- and long-term development strategy. At the same time, we maintain a balance with dividend stocks to provide dynamic, stable cash flow, keeping that exposure. But with the release of our New Year outlook, there are two sector allocation adjustments. First, we have officially upgraded biopharma within the healthcare sector to overweight. As I have mentioned in previous sessions, as global yields moderate, there is significant support for the sector's valuation and the return-on-cash-flow calculation. It will also encourage many capital market activities globally to restart and flourish. Correspondingly, we have officially downgraded the internet sector to underweight. On one hand, we still see many persistent macro challenges. On the other hand, especially recently, we expect greater uncertainty around mutual restrictions between China and the US in the technology sphere. This is more likely to manifest in an elevated overall risk premium, which has a relatively larger impact on large-cap, highly liquid internet companies. In 2027, we also want to emphasize that we do indeed view the uncertainty in China-US relations, especially around restrictive measures in technology, as the biggest short-term risk. Other risks include the significant risk of market earnings expectations being revised downward, as we just mentioned, all of which are factors we need to consider.
Four Key Trades to Focus on in 2027
For 2027, we strongly recommend four main trades. First, we remain more bullish on A-shares as a gathering place for new quality productive forces, with continued support from national team capital. Second, within the AI trade, we recommend clearly distinguishing between beneficiaries of domestic substitution and participants in the global supply chain. We strongly suggest focusing more on all beneficiaries along the domestic substitution theme, and we have provided the corresponding stock lists. Third, in our heavyweight blue book published last Thursday, the most representative new quality productive forces include companies that have already achieved relatively high market share, as well as rising stars we see emerging across various fields. We recommend carefully selecting stocks within this group for allocation. Fourth, reflecting our combination of macro and micro narratives, we have our China Focus List and our A-share精选 stocks. Based on our back-tested performance, these have consistently outperformed their respective market benchmark indices, and we recommend them for reference.
Comments